Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have been given a consensus rating of “Hold” by the seven research firms that are presently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $25.75.

Several equities research analysts have recently issued reports on ATRA shares. Canaccord Genuity reiterated a “buy” rating and set a $47.00 price objective on shares of Atara Biotherapeutics in a research report on Friday, April 21st. Jefferies Group LLC reiterated a “buy” rating and set a $30.00 price objective on shares of Atara Biotherapeutics in a research report on Thursday, June 22nd. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, June 27th. William Blair reiterated an “outperform” rating on shares of Atara Biotherapeutics in a research report on Monday, June 26th. Finally, ValuEngine cut shares of Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 1st.

In related news, EVP Christopher Haqq sold 6,000 shares of the business’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $12.65, for a total value of $75,900.00. Following the sale, the executive vice president now owns 368,080 shares in the company, valued at $4,656,212. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Isaac E. Ciechanover sold 6,900 shares of the business’s stock in a transaction on Wednesday, May 31st. The stock was sold at an average price of $13.35, for a total transaction of $92,115.00. Following the completion of the sale, the chief executive officer now owns 731,859 shares in the company, valued at approximately $9,770,317.65. The disclosure for this sale can be found here. Insiders sold 40,850 shares of company stock worth $591,296 in the last 90 days. 16.10% of the stock is currently owned by company insiders.

A number of large investors have recently made changes to their positions in the company. State Street Corp boosted its stake in shares of Atara Biotherapeutics by 62.8% in the fourth quarter. State Street Corp now owns 600,521 shares of the biotechnology company’s stock valued at $8,526,000 after buying an additional 231,541 shares in the last quarter. Norges Bank purchased a new position in Atara Biotherapeutics during the fourth quarter worth $4,031,000. Teachers Advisors LLC boosted its position in Atara Biotherapeutics by 5.5% in the fourth quarter. Teachers Advisors LLC now owns 137,416 shares of the biotechnology company’s stock worth $1,951,000 after buying an additional 7,165 shares during the period. Wells Fargo & Company MN boosted its position in Atara Biotherapeutics by 9.0% in the first quarter. Wells Fargo & Company MN now owns 58,252 shares of the biotechnology company’s stock worth $1,197,000 after buying an additional 4,791 shares during the period. Finally, Jennison Associates LLC purchased a new position in Atara Biotherapeutics during the first quarter worth $829,000. Institutional investors own 78.21% of the company’s stock.

Shares of Atara Biotherapeutics (ATRA) traded down 3.34% during midday trading on Tuesday, hitting $14.45. 83,126 shares of the stock were exchanged. Atara Biotherapeutics has a 1-year low of $11.80 and a 1-year high of $23.40. The firm has a 50-day moving average of $15.04 and a 200-day moving average of $15.93. The company’s market capitalization is $441.58 million.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by $0.05. On average, equities analysts expect that Atara Biotherapeutics will post ($3.88) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/atara-biotherapeutics-inc-atra-given-consensus-recommendation-of-hold-by-analysts/1491862.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.